← Holders
Tri Locum Partners LP
What Tri Locum Partners LP reported holding on Form 13F for the quarter ended Sep 30, 2026.
CIK 1826434 · Filed Nov 16, 2026
- Positions
- 18
- Reported value
- $506.1M
- Opened
- 3
- Closed
- 4
- Other managers included
- 0
Values are as the managers reported them, in dollars.Open the Form 13F on SEC EDGAR
Quarters on file
- Sep 30, 2025$435.1M18 positions
- Dec 31, 2025$770.1M15 positions
- Mar 31, 2026$712.5M17 positions
- Jun 30, 2026$813.2M19 positions
- Sep 30, 2026$506.1M18 positions
| Security | Shares | Change | Value | Of portfolio |
|---|---|---|---|---|
VRTXVertex Pharmaceuticals Inc | 132.9K | −34.1% | $69.5M | 13.7% |
LLYEli Lilly & Co | 51K | −33.3% | $59M | 11.7% |
TEVATeva Pharmaceutical Industries Ltd | 1.2M | +63.9% | $48.5M | 9.6% |
AMRXAmneal Pharmaceuticals, Inc. | 2.3M | New | $46.9M | 9.3% |
DXCMDexCom Inc | 489.4K | −40.4% | $42.2M | 8.3% |
JAZZJazz Pharmaceuticals plc | 160.3K | −27.7% | $37.1M | 7.3% |
ARGXArgenx SE | 30.4K | −26.9% | $29.1M | 5.8% |
ASNDAscendis Pharma A/S | 118.4K | −54.2% | $27M | 5.3% |
AXSMAxsome Therapeutics, Inc. | 143.3K | −34.6% | $26.4M | 5.2% |
JNJJohnson & Johnson | 73.6K | −82.7% | $19.5M | 3.8% |
ELVNEnliven Therapeutics, Inc. | 410.2K | −52.7% | $18.8M | 3.7% |
UTHRUnited Therapeutics Corp | 33K | −29.8% | $17.9M | 3.5% |
MDGLMadrigal Pharmaceuticals, Inc. | 33.7K | −50.7% | $17M | 3.4% |
CELCCelcuity Inc. | 202.6K | New | $16.1M | 3.2% |
DNTHDianthus Therapeutics, Inc. | 177.2K | +46.8% | $15.6M | 3.1% |
RVMDRevolution Medicines, Inc. | 40K | −73.6% | $8.2M | 1.6% |
DFTXDefinium Therapeutics, Inc. | 144.4K | −11.4% | $5.5M | 1.1% |
VRDNViridian Therapeutics, Inc. | 90.1K | New | $1.9M | 0.4% |